Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57
Sara Piacentini, Simone La Frazia, Anna Riccio, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference
John H. Beigel, Hannah Nam, Peter L. Adams, et al.
Antiviral Research (2019) Vol. 167, pp. 45-67
Open Access | Times Cited: 166
The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
Luke D. Jasenosky, Cristhian Cadena, Chad E. Mire, et al.
iScience (2019) Vol. 19, pp. 1279-1290
Open Access | Times Cited: 127
A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19
Amit S. Lokhande, Padma V. Devarajan
European Journal of Pharmacology (2020) Vol. 891, pp. 173748-173748
Open Access | Times Cited: 102
Medicinal chemistry strategies toward host targeting antiviral agents
Xingyue Ji, Zhuorong Li
Medicinal Research Reviews (2020) Vol. 40, Iss. 5, pp. 1519-1557
Open Access | Times Cited: 94
Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?
Dina B. Mahmoud, Zayyanu Shitu, Ahmed Mostafa
Journal of Genetic Engineering and Biotechnology (2020) Vol. 18, Iss. 1, pp. 35-35
Open Access | Times Cited: 94
Next-Generation Phenotypic Screening in Early Drug Discovery for Infectious Diseases
Nathalie Aulner, Anne Danckaert, JongEun Ihm, et al.
Trends in Parasitology (2019) Vol. 35, Iss. 7, pp. 559-570
Open Access | Times Cited: 83
ERp57/PDIA3: new insight
Silvia Chichiarelli, Fabio Altieri, Giuliano Paglia, et al.
Cellular & Molecular Biology Letters (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 47
Calcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies
Sascha Berlansky, Matthias Sallinger, Herwig Grabmayr, et al.
Cells (2022) Vol. 11, Iss. 2, pp. 253-253
Open Access | Times Cited: 40
A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
Jean‐François Rossignol, Matthew Bardin, Jessica Fulgencio, et al.
EClinicalMedicine (2022) Vol. 45, pp. 101310-101310
Open Access | Times Cited: 40
Virus-like particles (VLPs): A promising platform for combating against Newcastle disease virus
Mohammad Sadegh Taghizadeh, Ali Niazi‎, Alireza Afsharifar
Vaccine X (2024) Vol. 16, pp. 100440-100440
Open Access | Times Cited: 10
SARS-CoV-2, More than a Respiratory Virus: Its Potential Role in Neuropathogenesis
Chitra Mohinder Singh Singal, Paritosh Jaiswal, Pankaj Seth
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 13, pp. 1887-1899
Closed Access | Times Cited: 60
Intracellular Redox-Modulated Pathways as Targets for Effective Approaches in the Treatment of Viral Infection
Alessandra Fraternale, Carolina Zara, Marta De Angelis, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3603-3603
Open Access | Times Cited: 42
From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
Stav Rakedzon, Ami Neuberger, Abraham J. Domb, et al.
Journal of Travel Medicine (2021) Vol. 28, Iss. 2
Open Access | Times Cited: 41
Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence
Anna Riccio, Silvia Santopolo, Antonio Rossi, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 5
Open Access | Times Cited: 29
The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs
Yanbai Li, Shanshan Huo, Zhe Yin, et al.
mBio (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 20
Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”
Yanbai Li, Shanshan Huo, Zhe Yin, et al.
mBio (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 6
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
Andrew V. Stachulski, Joshua Taujanskas, Sophie Pate, et al.
ACS Infectious Diseases (2020) Vol. 7, Iss. 6, pp. 1317-1331
Open Access | Times Cited: 46
Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review
Rami A. Al‐Horani, Srabani Kar
Viruses (2020) Vol. 12, Iss. 10, pp. 1092-1092
Open Access | Times Cited: 44
Endoplasmic Reticulum Chaperones in Viral Infection: Therapeutic Perspectives
Évelyne Kohli, Sébastien Causse, Valentin Baverel, et al.
Microbiology and Molecular Biology Reviews (2021) Vol. 85, Iss. 4
Open Access | Times Cited: 40
Protein disulfide isomerases (PDIs) negatively regulate ebolavirus structural glycoprotein expression in the endoplasmic reticulum (ER) via the autophagy-lysosomal pathway
Bin Wang, Jing Zhang, Xin Liu, et al.
Autophagy (2022) Vol. 18, Iss. 10, pp. 2350-2367
Open Access | Times Cited: 24
Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity
Miranda A. Lewis, Nicolás W Cortés-Penfield, Khalil Ettayebi, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 10
Open Access | Times Cited: 15
Antiviral Chemotherapy in Avian Medicine—A Review
Ines Szotowska, Aleksandra Ledwoń
Viruses (2024) Vol. 16, Iss. 4, pp. 593-593
Open Access | Times Cited: 4
Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches
Anna Bonomini, Beatrice Mercorelli, Arianna Loregian
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
Morbillivirus Replication and Immune Evasion: Implications for Vaccine Design
Ashok Kumar, Ram Kumar, Anil Gattani, et al.
IntechOpen eBooks (2025)
Closed Access
Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain
Paola Ripani, Johannes Delp, Konstantin Bode, et al.
Oncogene (2019) Vol. 39, Iss. 11, pp. 2345-2357
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top